Search companies

Live

Tuesday, 17 November 2026 · 580 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

LTR Pharma Secures Indian Patent for SPONTAN and ROXUS Technology

LTP: $0.455 +8.33% · MC: $86M

LTR Pharma has secured an Indian patent covering defined formulation characteristics of the nasal spray technology behind its SPONTAN and ROXUS erectile dysfunction treatments. Protection extends to May 2041, subject to maintenance requirements and continued validity. The company recently reported that the first ROXUS prescriptions had been fulfilled in the US and that more than 2,000 bottles of SPONTAN had been dispensed in Australia.

Source announcements: 2026-11-09 08:52 to 2026-11-09 08:52 Sydney time
Story updated 2026-11-09 10:24 Sydney time
SourcesLTR Secures Indian Patent Supporting SPONTAN and ROXUS
Comments